Source: Fox News
Summary
The U.S. Food and Drug Administration approved Rasonque, a new cancer treatment pill developed by Revolution Medicines, for patients with advanced pancreatic cancer. The drug targets the RAS protein, which drives tumor growth. The FDA called the approval a “new treatment option” and noted it was granted more than six months ahead of its review deadline. The drug was tested in a trial of 500 patients, showing a median survival of 13.2 months, compared to 6.7 months for standard chemotherapy. The approval followed Priority Review, Orphan Drug status, and a Breakthrough Therapy designation.
Our Reading
This guidance has been heard before.
Another drug, another breakthrough, another promise for a deadly disease.
Studies show better survival, but the numbers still fall short of a cure.
Regulators move quickly, but patients still face long waits and high costs.
The same problems persist, even as new solutions emerge.
Author: Evan Null
Approval and Development
Rasonque, developed by Revolution Medicines in California, was approved by the FDA for adults with metastatic pancreatic cancer that did not respond to prior treatments. The drug targets multiple forms of the RAS protein, which is known to drive tumor growth. The FDA approved the treatment more than six months ahead of its review deadline, highlighting the urgency of the situation.
The approval followed a randomized, open-label trial involving 500 patients with pre-treated metastatic disease. Those taking Rasonque achieved a median overall survival of 13.2 months, compared to 6.7 months in the standard chemotherapy group. The drug received Priority Review, Orphan Drug status, and Breakthrough Therapy designation to expedite its path to market.
The FDA also used its National Priority Voucher pilot program to speed up access to critical public health treatments. Before final approval, the agency issued a “safe to proceed” letter in May, allowing patients to receive the drug through an expanded access protocol.
Despite the approval, pancreatic cancer remains one of the deadliest forms of cancer, with pancreatic adenocarcinoma accounting for up to 95% of annual cases. The disease causes a disproportionately high number of cancer deaths due to late detection and rapid spread.
While the drug shows significant improvements in survival, the most frequent adverse events include rash, diarrhea, mouth sores, nausea, fatigue, and bleeding. The FDA and cancer advocacy groups view the approval as a major step forward in the treatment of pancreatic cancer.
